大洋生物
(003017)
| 流通市值：18.93亿 | | | 总市值：22.86亿 |
| 流通股本：8348.11万 | | | 总股本：1.01亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 558,889,838.38 | 278,128,254.27 | 1,045,439,587.88 | 747,305,412.73 |
| 营业收入 | 558,889,838.38 | 278,128,254.27 | 1,045,439,587.88 | 747,305,412.73 |
| 二、营业总成本 | 505,222,175.56 | 247,566,318.08 | 941,878,108.45 | 668,570,639.15 |
| 营业成本 | 430,234,437.63 | 212,882,272.71 | 806,050,789.68 | 570,929,692.37 |
| 税金及附加 | 3,989,654.21 | 2,377,527.23 | 9,378,061.53 | 6,924,330.72 |
| 销售费用 | 5,024,200.64 | 2,352,340.85 | 11,616,828.19 | 8,192,631.5 |
| 管理费用 | 42,780,128.24 | 21,175,680.53 | 75,200,728.66 | 57,893,992.78 |
| 研发费用 | 23,750,855.03 | 9,057,135.16 | 43,777,617.57 | 27,695,023.89 |
| 财务费用 | -557,100.19 | -278,638.4 | -4,145,917.18 | -3,065,032.11 |
| 其中:利息费用 | 1,668,569.83 | 785,640.18 | 4,290,748.64 | 3,371,603.38 |
| 其中:利息收入 | 4,737,807.34 | 2,408,094.86 | 8,919,647.71 | 6,441,764.33 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 84,184.79 | 44,728.43 | -1,463,335.26 | -69,624.24 |
| 加:投资收益 | -879,599.83 | -167,785.07 | 1,179,572.46 | -774,165.39 |
| 资产处置收益 | -21,124.68 | -21,124.68 | 2,049,686.99 | 15,787.61 |
| 资产减值损失(新) | -891,705.11 | -238,840.75 | -18,159,797.31 | -14,055,437.73 |
| 信用减值损失(新) | -445,236.67 | -2,040,079.32 | -781,223.62 | -541,569.53 |
| 其他收益 | 11,764,540.58 | 6,660,184.98 | 23,785,748.5 | 20,554,807.23 |
| 四、营业利润 | 63,278,721.9 | 34,799,019.78 | 110,172,131.19 | 83,864,571.53 |
| 加:营业外收入 | 97,011.56 | 4,704.13 | 276,718.59 | 99,035.05 |
| 减:营业外支出 | 64,275.82 | 44,126.03 | 3,597,394.35 | 1,883,182.41 |
| 五、利润总额 | 63,311,457.64 | 34,759,597.88 | 106,851,455.43 | 82,080,424.17 |
| 减:所得税费用 | 6,388,370.45 | 3,855,725.63 | 6,787,143.78 | 2,421,380.2 |
| 六、净利润 | 56,923,087.19 | 30,903,872.25 | 100,064,311.65 | 79,659,043.97 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 56,923,087.19 | 30,903,872.25 | 100,064,311.65 | 79,659,043.97 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 57,469,343.79 | 30,870,752.17 | 99,854,406.02 | 80,036,566 |
| 少数股东损益 | -546,256.6 | 33,120.08 | 209,905.63 | -377,522.03 |
| 扣除非经常损益后的净利润 | 53,740,430.05 | 28,426,833.33 | 92,754,003.95 | 74,983,571.02 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.59 | 0.38 | 1.23 | 0.98 |
| (二)稀释每股收益 | 0.58 | 0.38 | 1.21 | 0.98 |
| 九、综合收益总额 | 56,923,087.19 | 30,903,872.25 | 100,064,311.65 | 79,659,043.97 |
| 归属于母公司股东的综合收益总额 | 57,469,343.79 | 30,870,752.17 | 99,854,406.02 | 80,036,566 |
| 归属于少数股东的综合收益总额 | -546,256.6 | 33,120.08 | 209,905.63 | -377,522.03 |
| 公告日期 | 2026-08-25 | 2026-04-28 | 2026-04-28 | 2025-10-21 |
| 审计意见(境内) | | | 标准无保留意见 | |